Novel Immunotherapy Combinations for NSCLC – OncLive
OncLive |
Novel Immunotherapy Combinations for NSCLC
OncLive Vassiliki A. Papadimitrakopoulou, MD: ECHO-202 is a combination therapy of epacadostat and pembrolizumab in patients that are immunotherapy naïve with non–small cell lung cancer. Very early results are encouraging. We're seeing response rates in the … |
